Targeted Thromboelastographic (TEG) Blood Component and Pharmacologic Hemostatic Therapy in Traumatic and Acquired Coagulopathy

Author(s): Mary K Bader, Francis J. Castellino, Victoria Ploplis, Faisal Shariff, Anton Crepinsek, Scott Thomas, Alyson Liew-Spilger, Sophia Binz, Jonathon McCollester, Mark Walsh, Adam Miller, Braxton Fritz, Swetha Chitta, Manar Jbara, Sarah Greve, Michael Son, Daniel Hake and Stephanie Fritz

Volume 17, Issue 8, 2016

Page: [954 - 970] Pages: 17

DOI: 10.2174/1389450117666160310153211

open access plus


Trauma-induced coagulopathy (TIC) is a recently described condition which traditionally has been diagnosed by the common coagulation tests (CCTs) such as prothrombin time/international normalized ratio (PT/INR), activated partial thromboplastin time (aPTT), platelet count, and fibrinogen levels. The varying sensitivity and specificity of these CCTs have led trauma coagulation researchers and clinicians to use Viscoelastic Tests (VET) such as Thromboelastography (TEG) to provide Targeted Thromboelastographic Hemostatic and Adjunctive Therapy (TTHAT) in a goal directed fashion to those trauma patients in need of hemostatic resuscitation. This review describes the utility of VETs, in particular, TEG, to provide TTHAT in trauma and acquired non-trauma-induced coagulopathy.

Keywords: Thromboelastography, point-of-care, acquired coagulopathy, blood component therapy, systemic hemostatic agents, trauma-induced coagulopathy, hemostatic resuscitation, tranexamic acid, targeted pharmacologic therapy.

« Previous
Graphical Abstract

© 2022 Bentham Science Publishers | Privacy Policy